Sort   by:  
 Page size 
UnknownPredictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study.
Not available
S-EPMC12273735 | biostudies-literature
UnknownExtended adjuvant tamoxifen for early breast cancer: a meta-analysis.
Not available
S-EPMC3930532 | biostudies-literature
UnknownClinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.
Not available
S-EPMC11333991 | biostudies-literature
UnknownFragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Not available
S-EPMC8366090 | biostudies-literature
UnknownTrastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Not available
S-EPMC3950860 | biostudies-literature
UnknownClinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
Not available
S-EPMC11099684 | biostudies-literature
UnknownA genome-wide association analysis for porcine serum lipid traits reveals the existence of age-specific genetic determinants.
Not available
S-EPMC4164741 | biostudies-literature
UnknownSrc, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
Not available
S-EPMC4134494 | biostudies-literature
UnknownDietary intake of bioactive ingredients impacts liver and adipose tissue transcriptomes in a porcine model of prepubertal early obesity.
Not available
S-EPMC7096439 | biostudies-literature
UnknownFactors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA.
Not available
S-EPMC11947834 | biostudies-literature
Sort   by:  
 Page size